Health Technology
Shionogi & Co., Ltd.
In the news
- Japan to shoulder COVID vaccine liability risks Aug 20, 2020
- AstraZeneca to supply Japan with 120m COVID-19 vaccine doses Aug 8, 2020
- Shionogi to ready COVID-19 vaccines for 30m people Jul 20, 2020
- Japan reveals 87 projects eligible for 'China exit' subsidies Jul 18, 2020
- Japan and Western drugmakers launch $1bn fund against superbugs Jul 10, 2020 See more articles on Shionogi & Co., Ltd.
Business Summary
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.
Financial Highlights
| Mar 2021 | JPY | USD |
| Revenue | 297,177M | 2,802.03M |
| Gross Profit | 238,000M | 2,244.06M |
| Operating income | 95,694M | 902.28M |
| Income before tax | 143,018M | 1,348.49M |
| Net income | 111,858M | 1,054.69M |
| EBITDA | 110,403M | 1,040.97M |
| Diluted EPS | 364.88 | 3.44 |
| Dividends Per Share | 108 | 1.01 |
| Total Assets | 998,992M | 9,040.65M |
| Total liabilities | 134,156M | 1,214.08M |
| Total equity | 846,108M | 7,657.08M |
| Operating cash flow | 109,039M | 1,028.11M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | |
| Revenue | 338,890M | 344,667M | 367,960M | 333,371M | 297,177M |
| Gross Profit | 261,113M | 270,756M | 305,713M | 270,117M | 238,000M |
| Operating income | 108,179M | 115,219M | 168,370M | 130,609M | 95,694M |
| Income before tax | 122,695M | 137,378M | 174,043M | 158,516M | 143,018M |
| Net income | 83,878M | 108,866M | 137,190M | 122,193M | 111,858M |
| EBITDA | 124,519M | 134,226M | 187,074M | 144,649M | 110,403M |
| Diluted EPS | 255.87 | 337.42 | 434.70 | 395.28 | 364.88 |
| Dividends Per Share | 72 | 82 | 94 | 103 | 108 |
| Total Assets | 670,271M | 711,463M | 938,540M | 873,695M | 998,992M |
| Total liabilities | 144,058M | 106,619M | 125,125M | 108,186M | 134,156M |
| Total equity | 522,737M | 601,374M | 808,774M | 765,152M | 846,108M |
| Operating cash flow | 111,903M | 129,790M | 165,000M | 131,940M | 109,039M |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | |
| Revenue | 3,129.53M | 3,109.80M | 3,318.10M | 3,066.16M | 2,802.03M |
| Gross Profit | 2,411.29M | 2,442.93M | 2,756.78M | 2,484.38M | 2,244.06M |
| Operating income | 998.99M | 1,039.57M | 1,518.28M | 1,201.26M | 902.28M |
| Income before tax | 1,133.04M | 1,239.51M | 1,569.44M | 1,457.94M | 1,348.49M |
| Net income | 774.58M | 982.25M | 1,237.11M | 1,123.86M | 1,054.69M |
| EBITDA | 1,149.89M | 1,211.07M | 1,686.95M | 1,330.40M | 1,040.97M |
| Diluted EPS | 2.36 | 3.04 | 3.92 | 3.63 | 3.44 |
| Dividends Per Share | 0.66 | 0.73 | 0.84 | 0.94 | 1.01 |
| Total Assets | 6,015.17M | 6,689.82M | 8,479.37M | 8,093.14M | 9,040.65M |
| Total liabilities | 1,292.81M | 1,002.52M | 1,130.46M | 1,002.13M | 1,214.08M |
| Total equity | 4,691.16M | 5,654.66M | 7,306.98M | 7,087.69M | 7,657.08M |
| Operating cash flow | 1,033.38M | 1,171.04M | 1,487.89M | 1,213.51M | 1,028.11M |
Valuation Measures
| Mar 2021 | |
| PER | 16.30 |
| ROA | 11.94% |
| ROE | 13.88% |
| Operating margin | 32.20% |
| Profit margin | 37.64% |
Key executives
- President & Representative Director: Isao Teshirogi
- Director & Executive Vice President: Takuko Sawada
- Executive Officer: Takeshi Shiota
- Executive Officer: Miyuki Hiura
- Executive Officer & Personnel Manager: Noriyuki Kishida
Shareholders
- Nomura Asset Management Co., Ltd. (6.8%)
- Sumitomo Life Insurance Co. (5.9%)
- Shionogi & Co., Ltd. (3.2%)
- Sumitomo Mitsui Banking Pension Fund (3.0%)
- Daiwa Asset Management Co. Ltd. (2.9%)
- Nikko Asset Management Co., Ltd. (2.9%)
- Nippon Life Insurance Co. (2.6%)
- The Vanguard Group, Inc. (2.2%)
- Edgepoint Investment Group, Inc. (2.0%)
- Ping An Insurance (Group) Co. of China Ltd. (2.0%)
Contact Details
- Website:http://www.shionogi.co.jp
- Address: 3-1-8 Dosho-machi, Chuo-Ku, Osaka, 541-0045, Japan
- Phone: +81.6.6202.2161
Related Companies
- Shionogi Singapore Pte Ltd.
- Shionogi Marketing Solutions Co., Ltd.
- Shionogi Pharmacovigilance Center Co., Ltd.
- Shionogi Business Partner Co., Ltd.
- Shionogi Digital Science Co., Ltd
- Shionogi Career Development Center Co., Ltd.
- Shionogi TechnoAdvance Research Co., Ltd.
- Shionogi BV
- Shionogi Pharma Co., Ltd.
- Shionogi Healthcare Co. Ltd.
- Shionogi & Co., Ltd. /2 Subsidiaries/
- Shionogi & Co. Restricted Stock Compensation Plan
- Shionogi Healthcare & Co., Ltd.
- Pionnier KK
- Shionogi USA Holdings, Inc.
- Beijing Shionogi Pharmaceutical Technology Ltd.
- Shionogi Ltd.
- Ezose Sciences, Inc.
- Shionogi, Inc.
- Shionogi Institute for Medical Science
- Aburahi Laboratories
- Taiwan Shionogi & Co., Ltd.
- Shionogi Pharma Chemicals Co., Ltd.
- Shionogi General Service Co., Ltd.
- Shionogi Bunseki Center KK
- Shionogi Ireland Ltd.
- Shionogi Engineering Service Co. Ltd.
- UMN Pharma, Inc.
- Shionogi Bioresearch Corp.
- Shionogi & Co. Ltd. Pension Fund
Competitors
- Vaxart, Inc.
- NanoViricides, Inc.
- CytoDyn Inc.
- Cocrystal Pharma Inc
- Entasis Therapeutics Holdings, Inc.
- Nabriva Therapeutics Plc
- Spero Therapeutics, Inc.
- TaiMed Biologics Inc.
- aTyr Pharma, Inc.
- BioCryst Pharmaceuticals, Inc.
- Trevi Therapeutics, Inc.
- Iterum Therapeutics plc
- Acura Pharmaceuticals, Inc.
- Aptamer Sciences, Inc.
- BELLUS Health Inc.
- Nektar Therapeutics
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 17 Sep, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.